FDA approves new drug for thyroid cancer

On February 13, the U.S. Food and Drug Administration (FDA) approved Lenvima (lenvatinib) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).

LEAVE A REPLY

Please enter your comment!
Please enter your name here